Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19
Open Access
- 4 March 2021
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 77 (9) , 1297-1307
Abstract
Aims: SARS-CoV-2 is a single-stranded RNA virus which is part of the ß-coronavirus family (like SARS 2002 and MERS 2012). The high prevalence of hospitalization and mortality, in addition to the lack of vaccines and therapeutics, forces scientists and clinicians around the world to evaluate new therapeutic options. One strategy is the repositioning of already known drugs, which were approved drugs for other indications.Subject and method: SARS-CoV-2 entry inhibitors, RNA polymerase inhibitors, and protease inhibitors seem to be valuable targets of research. At the beginning of the pandemic, theClinicalTrials.govwebpage listedn=479 clinical trials related to the antiviral treatment of SARS-CoV-2 (01.04.2020, “SARS-CoV-2,” “COVID-19,” “antivirals,” “therapy”), of whichn=376 are still accessible online in January 2021 (10.01.2021). Taking into account further studies not listed in the CTG webpage, this narrative review appraises HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors as promising candidates for the treatment of COVID-19.Results: Lopinavir/ritonavir, darunavir/cobicistat, remdesivir, tenofovir-disoproxilfumarate, favipriravir, and sofosbuvir are evaluated in clinical studies worldwide. Study designs show a high variability and results often are contradictory. Remdesivir is the drug, which is deployed in nearly 70% of the reviewed clinical trials, followed by lopinavir/ritonavir, favipiravir, ribavirine, and sofosbuvir.Discussion: This review discusses the pharmacological/clinical background and questions the rationale and study design of clinical trials with already approved HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors which are repositioned during the SARS-CoV-2 pandemic worldwide. Proposals are made for future study design and drug repositioning of approved antiretroviral compounds.Keywords
Funding Information
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
This publication has 47 references indexed in Scilit:
- NRTI Backbone in HIV TreatmentDrugs, 2012
- 1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYSJournal of Hepatology, 2012
- Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cellsJournal of Antimicrobial Chemotherapy, 2009
- Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitorsJournal of Theoretical Biology, 2008
- Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV MproBioorganic & Medicinal Chemistry, 2008
- Lopinavir/rotinavir: Appraisal of its use in HIV therapyDrugs of Today, 2007
- In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compoundsJournal of Clinical Virology, 2004
- Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral DrugsEmerging Infectious Diseases, 2004
- Short-term outcome of critically ill patients with severe acute respiratory syndromeIntensive Care Medicine, 2004
- SARS: pharmacotherapyRespirology, 2003